Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) has been given a consensus rating of "Moderate Buy" by the ten research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $32.90.
A number of research firms have recently weighed in on NRIX. HC Wainwright dropped their target price on shares of Nurix Therapeutics to $53.00 in a report on Thursday, October 13th. Morgan Stanley assumed coverage on Nurix Therapeutics in a research note on Tuesday, October 11th. They set an "equal weight" rating and a $11.00 target price on the stock. Finally, SVB Leerink cut their price target on shares of Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a report on Tuesday, December 13th.
Get
Nurix Therapeutics alerts:
Nurix Therapeutics Stock Up 7.3 %
Shares of NASDAQ NRIX opened at $13.26 on Friday. The firm's fifty day moving average is $11.69 and its 200 day moving average is $13.45. Nurix Therapeutics has a 52 week low of $7.52 and a 52 week high of $20.20. The company has a market cap of $625.21 million, a price-to-earnings ratio of -3.57 and a beta of 1.65.
Institutional Trading of Nurix Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its stake in Nurix Therapeutics by 11.0% during the third quarter. BlackRock Inc. now owns 3,723,090 shares of the company's stock worth $48,512,000 after acquiring an additional 367,743 shares in the last quarter. State Street Corp boosted its position in shares of Nurix Therapeutics by 9.2% in the 3rd quarter. State Street Corp now owns 2,312,224 shares of the company's stock worth $30,128,000 after purchasing an additional 195,453 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Nurix Therapeutics by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company's stock worth $28,156,000 after buying an additional 49,370 shares during the last quarter. ARK Investment Management LLC increased its position in Nurix Therapeutics by 54.5% during the 4th quarter. ARK Investment Management LLC now owns 1,988,254 shares of the company's stock valued at $21,831,000 after buying an additional 701,732 shares in the last quarter. Finally, Bain Capital Life Sciences Investors LLC increased its position in Nurix Therapeutics by 41.9% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 1,822,883 shares of the company's stock valued at $23,096,000 after buying an additional 538,570 shares in the last quarter. 91.33% of the stock is owned by hedge funds and other institutional investors.
About Nurix Therapeutics
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
